北歐時報特派記者楚善仁｜武漢報導
在全球醫療數位化浪潮中，人工智慧正逐步成為推動醫療變革的核心力量。從輔助診斷到疾病篩查，從智慧影像到遠程監控，AI技術正為全球健康領域注入前所未有的可能。而中國，憑藉強大的科技研發能力和龐大的臨床數據基礎，正逐步成為全球AI醫療領域的重要推手。
然而，當這些技術欲「走出去」，進軍國際市場，卻發現前路遠比想像中複雜。
從國內創新到全球應用：蘭丁智能的縮影
位於武漢光谷的蘭丁智能科技有限公司是一家以AI輔助癌症篩查為核心的創新企業。兰丁构建了Al+大数据云宫颈癌筛查的智能化数字化远程化产业链，完成了人工智能宫颈癌细胞诊断机器人“Landing”的自主研发及产业化，在全世界首创大规模宫颈癌筛查专家共享、数据共享和资源共享的云诊断平台。兰丁人工智能宫颈癌筛查技术通过了中国NMPA、美国FDA、欧盟CE等认证，获得了多项国家专利，广泛应用于政府大规模筛查项目。该技术规模经济效应显明，成本低，效率高，化解了基层缺乏细胞病理医生的难题，突破了地域、时间、应用场景等限制，以经济有效的Al技术和商业模式，把实现宫颈癌筛查全覆盖、切实降低宫颈癌发病率和死亡率变为现实。
作為創辦人，現年70歲的孫小蓉博士24年前從加拿大帶回一台醫療設備回國創業，從零起步。在湖北省政府大力支持下，她一步一腳印，把蘭丁從小型創業公司帶入全球AI醫療第一梯隊。如今，她的油畫作品掛滿公司走廊，科技與人文並存，成為蘭丁獨特的精神標誌。
但當企業計畫出海，進入歐洲與北美市場時，卻遭遇多重瓶頸。
三重挑戰：監管、信任與話語權
•法規與認證門檻高中國AI醫療產品要進入歐盟、美國市場，需符合當地醫療器械標準與數據保護規範。特別是AI演算法涉及臨床風險評估、模型可解釋性等嚴格要求，往往需要重複的審核與試驗。
•信任建構不易在AI尚未完全普及的醫療體系中，歐洲醫師與病患對中國技術仍存在一定認知距離。來自新興市場的企業需付出更多努力說明、試點與建立長期合作關係。
•標準話語權缺失當前全球醫療AI的標準制定仍以歐美主導，中國企業即便技術先進，若無法參與國際標準制定，就難以在市場中擁有定價與定義能力。
機遇何在？建立“技術+制度”的雙引擎
儘管挑戰重重，但AI醫療的全球需求卻從未如此強烈。歐洲正面臨醫療人力短缺、人口老齡化與公共衛生成本上升，對於能提升效率與準確率的AI輔助工具展現高度興趣。
對此，孫小蓉提出三項建議：
•加強國家層級合作：中國政府可推動與歐盟、北歐國家建立「數位健康合作框架」，促進雙邊醫療器械標準互認。
•民間與學術共同發聲：鼓勵企業與歐洲高校、醫院開展聯合研究與臨床試點，提升中國AI的國際學術能見度。
•打造“中國健康品牌”：透過國際媒體與平台，講述企業故事與社會影響力，建立信任與文化連結。
結語：從科技強國走向全球公衛貢獻者
AI醫療的「出海之路」不僅是商業擴張，更是一場國際合作與標準博弈的試煉。當一位來自武漢的女性企業家，從畫筆到演算法，用實力與溫度書寫著中國AI醫療的故事，我們看見的，不只是中國創新的力量，更是華人科技走向世界的決心。
中國AI醫療，未來可期。但唯有在技術與制度雙重維度上持續深耕，這場航行，才能真正駛向遠方。
AI-Powered Healthcare Goes Global:Opportunities and Challenges for Chinese Enterprises
By Chu Shanren,Special Correspondent for Nordic Chinese Times|Reporting from Wuhan
Amid the global wave of healthcare digitalization,artificial intelligence(AI)is gradually becoming the driving force behind transformative changes in the medical field.From assisted diagnosis to disease screening,smart imaging to remote monitoring,AI technology is injecting unprecedented potential into global health systems.China,with its robust R&D capabilities and vast clinical data resources,is emerging as a key player in the global AI healthcare landscape.
However,when these technologies attempt to"go global"and enter international markets,the journey proves far more complex than initially expected.
From Domestic Innovation to Global Application:The Story of Landing Intelligent
Located in Wuhan’s Optics Valley,Landing Intelligent Technology Co.,Ltd.is an innovative company focused on AI-assisted cancer screening.The company has developed a smart,digital,and remote AI+Big Data cervical cancer screening industry chain.Its independently developed AI-powered cytology diagnostic robot"Landing"has been successfully industrialized,pioneering a global cloud-based diagnostic platform for expert sharing,data sharing,and resource integration in large-scale cervical cancer screening.
Landing’s AI cervical cancer screening technology has passed certifications from China’s NMPA,the U.S.FDA,and the EU’s CE,and has secured numerous national patents.Widely used in government-led mass screening programs,the technology demonstrates clear economies of scale—low cost,high efficiency—and effectively addresses the shortage of cytopathologists in rural areas.It overcomes limitations of geography,time,and application scenarios,making full cervical cancer screening coverage and significantly reducing incidence and mortality rates an achievable reality through economical and efficient AI technology and business models.
Dr.Sun Xiaorong,the company’s70-year-old founder,brought a single medical device back from Canada24years ago to start her business from scratch.With strong support from the Hubei provincial government,she steadily grew Landing from a small startup into a leading player in global AI healthcare.Today,her oil paintings hang throughout the company’s corridors—symbolizing a unique blend of technology and humanity that defines Landing’s spirit.
However,as the company aims to expand overseas into Europe and North America,it faces multiple bottlenecks.
Triple Challenges:Regulation,Trust,and Voice
•High regulatory and certification thresholds
For Chinese AI healthcare products to enter the EU or U.S.markets,they must meet stringent local medical device standards and data protection regulations.In particular,AI algorithms are subject to strict requirements in clinical risk assessment and model interpretability,often requiring repeated reviews and trials.
•Building trust is not easy
In healthcare systems where AI is not yet widely adopted,there remains a perceptual gap among European doctors and patients regarding Chinese technologies.Enterprises from emerging markets must invest additional efforts in demonstrations,pilot programs,and establishing long-term partnerships.
•Lack of influence in standard-setting
Currently,global standards for medical AI are largely dictated by the West.Even with advanced technology,Chinese companies find it difficult to gain pricing and definitional power in the market if they are excluded from international standard-setting bodies.
Where Are the Opportunities?Building a Dual Engine of Technology+Policy
Despite the hurdles,the global demand for AI healthcare has never been stronger.Europe is facing medical workforce shortages,aging populations,and rising public health costs,creating a strong appetite for AI tools that enhance efficiency and accuracy.
In response,Dr.Sun Xiaorong offers three strategic suggestions:
•Strengthen national-level collaboration
The Chinese government can promote the establishment of"Digital Health Cooperation Frameworks"with the EU and Nordic countries to encourage mutual recognition of medical device standards.
•Joint efforts from private and academic sectors
Encourage Chinese companies to collaborate with European universities and hospitals on joint research and clinical pilots to enhance the global academic visibility of Chinese AI technologies.
•Build a"China Health Brand"
Use international media and platforms to share enterprise stories and social impact,fostering trust and cultural connection through narrative and transparency.
Conclusion:From a Tech Powerhouse to a Global Public Health Contributor
The journey of AI healthcare going global is not merely about business expansion—it’s a test of international cooperation and standard-setting influence.When a female entrepreneur from Wuhan bridges oil painting and algorithms to tell the story of Chinese AI healthcare with strength and warmth,what we witness is not only the power of Chinese innovation,but the unwavering resolve of Chinese technology to reach the world stage.
The future of China’s AI healthcare is bright—but only through continuous advancement in both technology and policy can this voyage truly sail into the distance.
